Moderna cancer vaccine leak

Lifestyle · Heat 10.0 / 10 · 3 shows · 27m airtime

On October 2, 2026, embargoed phase three results for Moderna's mRNA cancer therapy, given with Merck's Keytruda, leaked two days before a scheduled presentation via Oncology Central. The trial of 1,137 patients succeeded, but the reduction in recurrence or death came in at 42% versus 49% in phase two, and Moderna stock fell 26% intraday before closing down 18%. Discussion has settled on that gap as the number behind the selloff, with later reads framing the same data as a roughly 40% reduction in melanoma spread risk versus standard immunotherapy. A separate thread now covers a trader who sold Moderna calls at a loss and put roughly $500,000 into puts hours before the leak.

How 3 podcasts covered it

1. TBPN, 2026-10-23 (1:31 to 7:09)
   Walks through the leaked phase three data
   Walks through the leaked phase three data and the phase two anchor: the 49% relative risk reduction versus 42% in the larger trial, the six-month onset, and the 26% intraday plunge. Frames it as a miss against investor expectations, not a failed trial.
   New angle: The leaked phase three data showed a 42% reduction in recurrence or death, below phase two's 49%.
2. TBPN, 2026-10-23 (7:13 to 12:47)
   Retells the influencer's Moderna trade
   Tells the Togi story: the influencer's dream-driven Moderna calls, his $200,000 drawdown, and the flip to puts hours before the leak-driven crash. A colorful retelling of the fallout that stays inside the leak narrative.
3. WSJ What's News, 2026-10-23 (8:25 to 11:00)
   Explains the leak behind the selloff
   Explains the investor disappointment by tracing it to August, when Merck and Moderna said the trial met two goals without releasing data, and sets the 40% spread-risk reduction against a $240 billion oncology market. Notes the approval filing and launch timeline could slip.
   New angle: The leaked data showed a roughly 40% reduction in melanoma spread risk versus standard immunotherapy.
4. TBPN, 2026-10-23 (1:16 to 6:36)
   Breaks down the leaked trial numbers
   Walks through the leak and the numbers behind the selloff: the phase 3 trial of 1,137 patients succeeded but delivered a 42% reduction in recurrence risk against phase 2's 49%, and the treatment only starts working after six months. Frames it against Moderna's long Theranos-era skepticism.
   New angle: The leaked phase 3 data showed a 42% reduction in recurrence risk, below the 49% from phase 2.
5. TBPN, 2026-10-23 (6:49 to 12:29)
   Adds the trader who flipped to puts
   Picks up the Moderna leak from the trading side: influencer Togi flipped his calls to puts hours before the crash, freeing roughly $500,000, and calls the timing a giga stroke of luck. A new first-hand account of the plunge, not new trial data.
   New angle: Togi sold his Moderna calls at a loss and put roughly $500,000 into puts hours before the leak.
6. The Readout Loud, 2026-10-30 (6:09 to 8:30)
   Recaps the embargo break and the sell-off
   Recaps the embargo break and the sell-off, framing the drop as a market reaction after Moderna added about $60 billion in market value since August, not a verdict on the data. Stays inside the leak coverage already on the record.